Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Integra Lifesciences Holdings (IART) Total Debt (2016 - 2025)

Integra Lifesciences Holdings' Total Debt history spans 17 years, with the latest figure at $1.7 billion for Q4 2025.

  • For Q4 2025, Total Debt rose 4.12% year-over-year to $1.7 billion; the TTM value through Dec 2025 reached $1.7 billion, up 4.12%, while the annual FY2025 figure was $1.7 billion, 4.12% up from the prior year.
  • Total Debt for Q4 2025 was $1.7 billion at Integra Lifesciences Holdings, down from $1.7 billion in the prior quarter.
  • Across five years, Total Debt topped out at $1.7 billion in Q3 2025 and bottomed at $769.1 million in Q1 2023.
  • The 5-year median for Total Debt is $870.5 million (2022), against an average of $1.1 billion.
  • The largest annual shift saw Total Debt dropped 14.76% in 2021 before it skyrocketed 98.28% in 2024.
  • A 5-year view of Total Debt shows it stood at $869.3 million in 2021, then fell by 11.27% to $771.3 million in 2022, then grew by 8.92% to $840.1 million in 2023, then surged by 97.73% to $1.7 billion in 2024, then rose by 4.12% to $1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for IART's Total Debt are $1.7 billion (Q4 2025), $1.7 billion (Q3 2025), and $1.7 billion (Q2 2025).